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Abstract
The purpose of this study was to identify attitudes and perceptions of willingness to partici-
pate in genetic testing for type 2 diabetes (T2D) risk prediction in the general population.
Adults (n = 598) were surveyed on attitudes about utilizing genetic testing to predict future
risk of T2D. Participants were recruited from public libraries (53%), online registry (37%)
and a safety net hospital emergency department (10%). Respondents were 37±11
years old, primarily White (54%), female (69%), college educated (46%), with an annual
income$25,000 (56%). Half of participants were interested in genetic testing for T2D
(52%) and 81% agreed/strongly agreed genetic testing should be available to the public.
Only 57% of individuals knew T2D is preventable. A multivariate model to predict interest in
genetic testing was adjusted for age, gender, recruitment location and BMI; significant pre-
dictors were motivation (high perceived personal risk of T2D [OR = 4.38 (1.76, 10.9)]; family
history [OR = 2.56 (1.46, 4.48)]; desire to know risk prior to disease onset [OR = 3.25 (1.94,
5.42)]; and knowing T2D is preventable [OR = 2.11 (1.24, 3.60)], intention (if the cost is free
[OR = 10.2 (4.27, 24.6)]; and learning T2D is preventable [OR = 5.18 (1.95, 13.7)]) and trust
of genetic testing results [OR = 0.03 (0.003, 0.30)]. Individuals are interested in genetic test-
ing for T2D risk which offers unique information that is personalized. Financial accessibility,
validity of the test and availability of diabetes prevention programs were identified as predic-
tors of interest in T2D testing.
Introduction
In the last decade over 140 novel genetic markers robustly associated with type 2 diabetes
(T2D)[1] and related traits[2] have been discovered. These discoveries are the building blocks
of personalized medicine–using patient genetic risk information to guide prevention, diagnosis
or treatment. A scientific framework has been proposed to evaluate genetic testing; the ACCE
model (analytic validity, clinical validity, clinical utility and the ethical, legal or social implica-
tion)[3]. The clinical validity of genetic markers adds only marginal value in predicting future
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development of T2D [4, 5], and have been shown to be independent of family history[6, 7].
The emerging scientific evidence for the clinical utility of genetic testing (genetic test results are
shown to improve health outcomes) for common diseases has shown mixed results[8] and
only one has been conducted for T2D[9].
Few studies have examined the characteristics and reasons associated with interest in
genetic testing for T2D risk[10]. Studies representing a broad range of common diseases found
that the characteristics associated with reluctance to pursue genetic testing included: anxiety
about genetic testing; older age; lower levels of education; and high perceived discrimination
from employers and insurers[11–14]. Evenmore studies have indicated high genetic risk for a
given disorder is associated with improved motivation to adopt a healthier lifestyle[9–11, 15–
18]. Specific to T2D, participants reported greater knowledge of genetics, high perceived risk of
T2D, and high motivation to adopt a healthier lifestyle were positively correlated with willing-
ness to obtain T2D genetic testing[9]. Nonetheless participants in these studies have been lim-
ited to either high-risk individuals, members of managed care organizations, or have been
predominantly well educated or white, non-Hispanic which has limited the generalizability of
these findings to populations representing the full spectrum of risk for T2D (i.e. no risk to high
risk). Moreover, studies have been limited in the breadth of psychosocial constructs measured
in their study population; primarily measuring factual knowledge of diseases or genetics, or
knowledge and attitudes of the benefit, consequence or intention to undergo genetic testing.
Through direct-to-consumer venues, genetic susceptibility testing for polygenic disorders
such as T2D have become available to the public. Genetic susceptibility testing offers personal-
ized and detailed risk information, which can also provide an opportunity to inform the public
about T2D development and prevention. The current research examined extensive attitudinal
factors affecting individuals’ decision to engage in genetic testing for T2D risk prediction in a
socioeconomically diverse population. The purpose of the current study was to identify predic-
tors of interest in genetic testing. We pose this question as a first step in understanding ways
this new risk factor identification tool maybe relevant to patients.
Materials and Methods
Participants
This study was approved by Indiana University Institutional Review Board (1205008781). All
participants provided written consent to participate in this study. Participants (n = 649) were
residents of Indiana between the ages of 18–64 years, and were recruited June-July 2012 from
14 public libraries across the greater Indianapolis metropolitan area (n = 344; 53% of total sam-
ple), the emergency department (ED) of Wishard Hospital (n = 62; 10%), and online (n = 243;
37%) through a volunteer research participant registry (INResearch.org). To recruit partici-
pants from public libraries or the ED, research assistants set up tables located inside the library
or the waiting room of the ED. Visitors of the public libraries or the ED were asked if they
would be interested in filling out a survey on genetic testing. Research assistants were at the
sites during peak hours for 1–2 days per library and 2 days at the ED. Participants of the volun-
teer registry received an email describing the study with a link to the online survey. To over-
sample groups that are often underrepresented in genetic testing (e.g. African-Americans,
lower socioeconomic status) the ED of Wishard Hospital was chosen. It is the safety net health
care system serving greater Indianapolis.
Questionnaire
The questionnaire was designed using standard survey development procedures[19]. An exten-
sive literature search was conducted on the assessment of attitudes, beliefs and behaviors
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associated with genetic testing in T2D and other chronic diseases to guide the questionnaire
design. An initial sample of 75 items were created and distributed to five experts in the fields of
psychology, sociology and anthropology for evaluation. Following revisions, items were piloted
in a focus group of N = 10 participants to assess clarity of wording. Based on feedback, items
were then edited resulting in a total of N = 59 items in the domains of demographic, personal
and family medical history, psychosocial and behavioral factors related to interest in genetic
testing for T2D risk prediction (S1 Appendix).
Demographic Characteristics. Age, gender, marital status, household income, education,
race, ethnicity, and type of health insurance data were gathered. Questions were adapted from
the 2010 U.S Census Bureau.
Personal and family health history. Participants answered questions on their personal
medical history by checking boxes listing 9 conditions related to diabetes, hypertension, high
cholesterol, heart disease, overweight/obese. Family history of T2D was measured with ‘Does
type 2 diabetes run in your family (blood relatives)?’ using a yes/no/don’t know response
format.
Psychosocial. Participants answered questions drawn from behavior change models [20]
which included perceived health, knowledge of T2D, perceived risk and worry of developing
T2D, awareness of genetic testing, trust of genetic results, motivation for and utility of genetic
testing, barriers to genetic testing, attitudes towards genetic testing and T2D prevention, inten-
tion for genetic testing, worry related to genetic testing procedure and results, motivation to
lower risk of T2D through lifestyle changes if genetic test results indicated high risk, and
knowledge of basic genetics. Many of the questions were adapted from state-level Behavioral
Risk Factor Surveillance Systems (BRFSS) questionnaires. Questions relating to worry were
measured using a seven-point Likert scale (“Not worried at all” to “Extremely worried”). Other
items had a five-point Likert scale (e.g. “Strongly agree”, “Agree”, “Neither agree nor disagree”,
“Disagree”, “Strongly disagree”) or multiple choice response format.
Perceived health. We measured perceived health with the following item: ‘In general, you
would describe your health as’ rated as Excellent/Very Good/Good/Fair/Poor[21].
T2D knowledge. Wemeasured knowledge of T2D with three questions. The first two
questions asked participants to check all boxes that applied. The first question asked ‘Which
options do you feel are true for type 2 diabetes?: type 2 diabetes can be cured, type 2 diabetes
can be prevented, type 2 diabetes is entirely inherited, type 2 diabetes is partly inherited and
partly due to lifestyle conditions, the risk of getting type 2 diabetes, cannot be changed, the risk
of getting type 2 diabetes can be changed, onset of type 2 diabetes can be delayed’. The second
question was ‘Which options do you think can delay the onset of type 2 diabetes?: healthier eat-
ing, regular exercise, medication, cannot delay the onset of type 2 diabetes, other’. The third
question was ‘If you get type 2 diabetes, then would you have an increased risk for other dis-
eases too?’ Yes/not sure/no.
Perceived risk and worry of T2D. Wemeasured perceived risk and worry of developing
T2D with one question for each, respectively, using the same general format: ‘On a scale of 1 to
7, how [likely do you think / worried are you that] you will get type 2 diabetes in the future?’.
Worry. We also measured worry with six questions using the same response format: ‘On a
scale of 1 to 7, how worried are you . . ..?’. The questions related to having genetic testing for
T2D, cost of testing, collecting a sample with saliva or with blood, results predict a high risk or
predict a low risk.
Awareness of genetic testing. We measured awareness of genetic testing with two ques-
tions on whether participants had ever heard of genetic testing (yes/no) and where they had
heard of genetic testing by checking all boxes listing media, physician, family, friends, teachers,
other.
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Trust. We measured trust in genetic testing by asking ‘If a genetic test shows that you are
at high risk for getting type 2 diabetes, you believe your actual risk for type 2 diabetes would be:
high, medium, low, none’.
Motivation. Motivation to have genetic testing for T2D risk assessment was measured
with three questions. The first question simply asked ‘your motivation to have genetic testing
for type 2 diabetes is: very high/high/average/low/very low’. For the next two questions, partici-
pants could check all boxes that applied. The questions were reasons for currently being moti-
vated (know someone with diabetes complications, family history, had diabetes during
pregnancy, diabetes is preventable, future treatment, know risk before development, currently
high risk, other) and options that would increase motivation (insurance covers cost, testing is
not expensive, pre-/post-test counseling is available, test is accurate, physician recommends,
family member with high genetic test results, other).
Attitudes. Wemeasured attitudes towards genetic testing with two questions. We asked
participants to identify reasons for rejecting genetic testing for type 2 diabetes, which included
low risk, no family history, genetic risk is not changeable, prefer cancer testing, testing would
be personally harmful, would be more worried if results showed high risk, no access to facilities
and services, do not trust results, no time, other. We asked ‘Assuming that type 2 diabetes is
completely preventable, would you now want genetic testing done for type 2 diabetes?’ using a
yes/no/not sure response format.
Utility. Wemeasured the perceived utility of genetic testing results by asking ‘Knowing
your type 2 diabetes genetic test results will be useful to you.’ Participants could check all boxes
that applied from a list of 7 items: uncertainty of risk would be clearer, can discuss results with
physician, can convince your family to be tested, can better prepare yourself for the future, test
results will motivate you to take actions to decrease risk, wanting to know results so their chil-
dren could also be tested, other.
Barriers to Genetic Testing. Wemeasured barriers to genetic testing by asking partici-
pants ‘Assuming genetic testing is free of cost, would you now want genetic testing done for
type 2 diabetes?’ Yes/no/not sure.
Genetic literacy. Participants answered five true/false questions that assessed general
knowledge of genetics. Questions were modified from existing measures of genetic literacy[16,
22, 23]. One point was given to each question answered correctly and summed to create a
genetics knowledge total score (range 0–5). A score of four or greater indicated high levels of
genetic knowledge.
Procedures
Questionnaires were self-administered using paper or web-based versions available in English
or Spanish (1.8% of total surveys). The online questionnaire was distributed to prospective par-
ticipants registered at Indiana’s volunteer research participant registry (INResearch.org). The
printed version of the questionnaire was handed to eligible participants by trained interviewers
at the public libraries or the ED waiting room of Wishard hospital in Indianapolis. After com-
pleting the survey, each study participant was compensated for his or her time with a $10 gift
card. After completing the survey, participants were offered educational materials describing
diabetes, risk factors and symptoms, and the Genetic Information Non-discrimination Act
(GINA bill). All materials were available in both English and Spanish.
Data Analysis
For all statistical analyses, SAS software version 9.4, was used. Individuals who self-reported
diabetes (n = 50) and BMI<15 kg/m2 (n = 1) were excluded from the sample. BMI was
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categorized using standard definitions: underweight/normal (BMI<25.0 kg/m2), overweight
(25.0–29.9 kg/m2), or obese (>30 kg/m2). The sample was grouped by interest in pursuing
T2D genetic testing (“Would you like to get genetic testing done for type 2 diabetes?” yes vs. no
or not sure). Differences in demographic and psychosocial variables by group were evaluated
using univariate logistic regression analyses. Bonferroni correction was applied for the
number of tests performed (Bonferroni correction = 0.05/70 = 0.0007). Multivariable logistic
regression analyses were computed to predict willingness to engage in T2D genetic testing
(yes) adjusted for age, gender, recruitment location and BMI (as a continuous variable). Vari-
ables that showed a significant relationship in the univariate models (p< .0007) were entered
into the multivariable models if they were not multicollinear (i.e. Pearson and Spearman Cor-
relations .40) or conceptually the same as the outcome variable.
Results
Participant Characteristics
Participants (n = 598) had a mean age of 37±11 years, were primarily White (54%), female
(69%), had no college degree (54%), private health insurance (52%) and an annual household
income of $25,000 or greater (56%; Table 1). The majority of participants self-reported BMI
values as being overweight (27%) or obese (35%) and a family history of T2D (42%). Eighty-
one percent of respondents agreed or strongly agreed with the statement ‘genetic testing should
be available to the public.’ Fifty-seven percent of participants reported knowledge that T2D is
preventable.
Factors Influencing Decisions to Engage in T2D Genetic Testing:
Univariate Analyses
Approximately half (52%) of the respondents indicated willingness to participate in genetic
testing to predict their T2D risk. Interest in genetic testing did not differ by age, gender, BMI,
race, marital status, education, annual household income levels, and health insurance
(p’s>.0007; Table 1). Individuals with a family history of T2D (48.1%) were more likely to
report an interest in T2D genetic testing (p = 0.0001; Table 1). The majority of respondents
scored high on questions pertaining to basic knowledge of genetics (86.8%), and were concep-
tually aware of genetic testing (62.5%) despite having no prior personal experience with genetic
testing (89.9%; Table 2). Genetic literacy, however, was not significantly associated with will-
ingness to engage in T2D genetic testing (p = 0.3; Table 2). Most adults believed they were in
excellent/very good/good health (82.5%), with a low (47%) or neutral risk (28%) of developing
T2D in the future (Table 2). Individuals who perceived themselves as having low risk of devel-
oping T2D were significantly less interested in genetic testing (p = 0.0004). Worry about per-
ceived risk of developing T2D significantly predicted the decision to consider genetic testing
for T2D risk (p = 0.0002).
When asked to rate reasons to consider T2D genetic testing, individuals rated the desire to
know risk prior to diagnosis as the most common reason (40.6%; Table 2) followed by:
knowledge that T2D is a preventable disease (36.2%), positive family history for T2D (33.2%),
knowing someone with T2D related complications (26.2%), possibility of gene therapy for T2D
in the future (23.7%), and high perceived personal risk (11.9%). Each of these reasons signifi-
cantly distinguished those with and without interest in genetic testing (p’s< .0001). Reasons
that increased motivation to engage in genetic testing were insurance coverage for the costs of
testing, and knowledge that the genetic test is accurate (p’s< .0001). Individuals interested in
genetic testing reported high/very high motivation to exercise (p = 0.0002).
Attitudes towards Genetic Testing for Type 2 Diabetes Risk Prediction
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Participants considered the test to be useful if the test results would lead them to do any of
the following: discuss their test results with their physician(s), change their level of risk, con-
vince their family member(s) to get tested, become motivated to have their children tested, bet-
ter prepare themselves for the future, and initiate preventive behaviors (p’s<0.0001; Table 2).
The most common reason to reject genetic testing was low perceived risk for developing T2D
in the future (10.4%, p<0.0001). Other psychosocial barriers (Table 2) to testing were: absence
of family history of T2D, prefer genetic testing for cancer risk prediction, anticipated worry
about the test results, and distrust of the test results (p’s<0.0001).
Table 1. Demographic Characteristics of the Study Population (n = 598).
Interest in T2D Genetic Testinga
Characteristic Total Yes (n = 312) No (n = 285) p-value
Age (years) 37±11 37±11 37±12 0.5918
Females 410 (68.9) 226 (72.4) 184 (65.0) 0.0509
BMI (kg/m2) 29.0±7.8 29.9±8.3 28.2±7.1 0.0085
Family History of T2D (Yes) 244 (41.6) 150 (49.2) 94 (33.5) 0.0001*
Race
White 307 (54.1) 161 (55.1) 146 (52.9) 0.5443
Black 217 (38.2) 106 (36.3) 111 (40.2)
Asian/Latino/Native American 44 (7.8) 25 (8.6) 19 (6.9)
Marital Status
Single 337 (56.5) 168 (54.0) 168 (59.2) 0.0054
Married 201 (33.8) 101 (32.5) 100 (35.2)
Cohabitating 58 (9.8) 42 (13.5) 16 (5.6)
Education
College or more 269 (45.9) 128 (42.2) 141 (49.8) 0.1948
Some college 146 (24.9) 83 (27.4) 63 (22.3)
Completed high school 98 (16.7) 56 (18.5) 42 (14.8)
Some/less high school 73 (12.5) 36 (11.9) 37 (13.1)
Annual Household Income
($) <25,000 255 (43.6) 134 (44.4) 121 (42.8) 0.6891
25,000–50,000 163 (27.9) 88 (29.1) 75 (26.5)
50,001–75,000 59 (10.1) 26 (8.6) 33 (11.7)
75,001–100,000 47 (8.0) 25 (8.3) 22 (7.8)
>100,000 61 (10.4) 29 (9.6) 32 (11.3)
Health Insurance
Commercial 300 (51.8) 159 (53.2) 141 (50.4) 0.1137
Medicare 38 (6.6) 16 (5.4) 22 (7.9)
Medicaid 86 (14.9) 52 (17.4) 56 (45.2)
None 155 (26.8) 72 (24.1) 83 (29.6)
Recruitment Location
Public Library 316 (53.0) 146 (46.8) 170 (59.9) 0.0025
Web survey 225 (37.8) 138 (44.2) 87 (30.6)
Emergency Department 55 (9.2) 28 (9.0) 27 (9.5)
Results are presented as mean±standard deviation or frequency.
aComparison between yes versus no interest in genetic testing.
*P-value remains signiﬁcant after Bonferonni correction; p<0.007.
doi:10.1371/journal.pone.0147071.t001
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Table 2. Univariate Analyses of Psychosocial Factors PredictingWillingness to Engage in Genetic Testing for Type 2 Diabetes Risk Prediction
(n = 598).
Interest in T2D Genetic Testing
Psychosocial Factor Total Yes (n = 312) No (n = 285) p-value
General Health: Good/Very/Excellent 495 (82.5) 245 (78.2) 249 (87.2) 0.0038
Risk Perception
Perceived T2D Risk: High 136 (23.3) 86 (28.3) 50 (17.9) 0.0004*
Neither 166 (28.4) 94 (30.9) 72 (25.7)
Low 282 (48.3) 124 (40.8) 158 (56.4)
Awareness
Genetic Testing is Available 370 (62.5) 195 (62.9) 175 (62.1) 0.8317
Source: Media 364 (61.1) 193 (61.9) 119 (38.1) 0.6803
Source: Physician 195 (32.7) 116 (37.2) 79 (27.8) 0.0150
Source: Family 185 (31.1) 99 (31.8) 86 (30.3) 0.6831
Source: Friends 108 (18.1) 57 (18.3) 51 (18.0) 0.9215
Source: Teachers 106 (17.8) 54 (17.3) 52 (18.3) 0.7493
Knowledge
T2D is Curable 104 (17.5) 48 (15.4) 56 (19.7) 0.1638
T2D is Preventable 342 (57.4) 188 (60.3) 154 (54.2) 0.1370
T2D is Inherited 53 (8.9) 28 (9.0) 25 (8.8) 0.9414
T2D is both Inherited and due to Lifestyle Conditions 376 (63.1) 210 (67.3) 166 (58.5) 0.0252
T2D Risk Can not be Changed 28 (4.7) 13 (4.2) 15 (5.3) 0.5205
T2D Risk Can be Changed 315 (52.9) 175 (56.1) 140 (49.3) 0.0970
Onset of T2D Can be Delayed 262 (44.0) 134 (43.0) 128 (45.1) 0.6022
T2D Onset Can be Delayed with Healthier Eating 532 (89.3) 285 (91.4) 247 (87.0) 0.0849
T2D Onset Can be Delayed with Regular Exercise 479 (80.4) 256 (82.1) 223 (78.5) 0.2785
T2D Onset Can be Delayed with Medication 234 (39.3) 128 (41.0) 106 (37.3) 0.3553
T2D Increases Risk of other Diseases 375 (64.0) 209 (67.9) 166 (59.7) 0.0403
Genetic Literacy: High 514 (86.8) 276 (88.8) 238 (84.7) 0.3429
Genetic Literacy: Average 52 (8.8) 23 (7.4) 29 (10.3)
Genetic Literacy: Low 26 (4.4) 12 (3.9) 14 (5.0)
Worry
Worry of acquiring T2D in the future: High 241 (41.2) 148 (48.5) 93 (33.2) 0.0002*
Worry about T2D Genetic Testing: High 154 (26.0) 84 (27.1) 70 (24.7) 0.5124
Worry about Cost of T2D Genetic Testing: High 429 (73.0) 240 (77.4) 189 (67.3) 0.0057
Worry from High Risk Testing Result: High 445 (75.3) 247 (79.7) 198 (70.5) 0.0095
Motivation
Motivation to have T2D Genetic Testing: High 205 (34.4) 185 (59.3) 20 (7.1) <0.0001*
Motivation to have T2D Genetic Testing: Average 237 (39.8) 106 (34.0) 131 (46.3)
Motivation to have T2D Genetic Testing: Low 153 (25.7) 21 (6.7) 132 (46.6)
Motivation Reasons: Want to Know Risk Before T2D Onset 242 (40.6) 186 (59.6) 56 (19.7) <0.0001*
Motivation Reasons: T2D is Preventable 216 (36.2) 151 (48.4) 65 (22.9) <0.0001*
Motivation Reasons: Family History 198 (33.2) 141 (45.2) 57 (20.1) <0.0001*
Motivation Reasons: Know Someone with T2D Complications 156 (26.2) 105 (33.7) 51 (18.0) <0.0001*
Motivation Reasons: Future Genetic Treatment for T2D 141 (23.7) 105 (33.7) 36 (12.7) <0.0001*
Motivation Reasons: Personal Risk 71 (11.9) 56 (18.0) 15 (5.3) <0.0001*
Motivation Reasons: History of Gestational Diabetes 17 (2.8) 13 (4.2) 4 (1.4) 0.0433
Motivation Increase: Insurance Covers Cost 370 (62.1) 221 (70.8) 149 (52.5) <0.0001*
(Continued)
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Participants were asked if their interest in genetic testing would change based on the test
being free of cost or T2D is preventable (p’s< .0001, Table 2). Among individuals not inter-
ested in testing (n = 285), 50% became interested if the test was free of cost and 64% became
interested if they were told that T2D is preventable.
Factors Influencing Decisions to Engage in T2D Genetic Testing:
Multivariable Analyses
Variables associated with interest in pursuing T2D genetic testing in the univariate models
were entered into multiple logistic regression analyses and were adjusted for age, gender, BMI
and recruitment location (Table 3). Psychosocial predictors that remained significantly
Table 2. (Continued)
Interest in T2D Genetic Testing
Psychosocial Factor Total Yes (n = 312) No (n = 285) p-value
Motivation Increase: Test is Accurate 312 (52.4) 198 (63.5) 114 (40.1) <0.0001*
Motivation Increase: Test is Inexpensive 254 (42.6) 150 (48.1) 104 (36.6) 0.0047
Motivation Increase: Physician Recommends Test 213 (35.7) 120 (38.5) 93 (32.8) 0.1459
Motivation Increase: Genetic Test Counseling Provided 205 (34.4) 124 (39.7) 81 (28.5) 0.0040
Motivation Increase: Relative with High Risk Test Result 153 (25.6) 91 (29.2) 62 (21.8) 0.0406
Action Motivation if High Risk Result: Healthier Eating (High/Very) 497 (84.4) 276 (89.0) 221 (79.2) 0.0010
Action Motivation if High Risk Result: Regular Exercise (High/Very) 485 (81.9) 272 (87.5) 213 (75.8) 0.0002*
Action Motivation if High Risk Result: Lose Weight (High/Very) 461 (78.1) 256 (82.5) 205 (73.2) 0.0060
Utility
Discuss T2D Genetic Test (GT) Results with Physician 265 (44.5) 171 (54.8) 94 (33.1) < .0001*
Uncertainty Clear 234 (39.3) 151 (48.4) 83 (29.2) < .0001*
Convince Family to get Tested 193 (32.4) 123 (39.4) 70 (24.7) 0.0001*
Test Children as well 157 (26.2) 103 (33.0) 54 (19.0) 0.0001*
Prepare for Future 364 (61.1) 230 (73.7) 134 (47.2) < .0001*
Start Preventive Actions 351 (59.1) 219 (70.7) 132 (46.5) < .0001*
Attitudinal Barriers to Testing
Perceived Low Risk 80 (13.4) 18 (5.8) 62 (21.8) < .0001*
Negative Family History of T2D 64 (10.7) 16 (5.1) 48 (16.9) < .0001*
Preference for Cancer GT than T2D Genetic Testing 55 (9.2) 15 (4.8) 40 (14.1) < .0001*
Anticipated Worry from Test Result 47 (7.9) 11 (3.5) 36 (12.7) < .0001*
Belief: Cannot Change Genetic Risk 42 (7.1) 14 (4.5) 28 (9.9) 0.0105
Lack of Time for T2D Genetic Testing 28 (4.7) 8 (2.6) 20 (7.0) 0.0099
Poor Access to Health Care 25 (4.2) 6 (1.9) 19 (6.7) 0.0037
Distrust in T2D Genetic Testing Results 17 (2.9) 1 (0.32) 16 (5.6) < .0001*
Harmful 14 (2.4) 5 (1.6) 9 (3.2) 0.2073
Trust
Availability of T2D Genetic Testing: Yes 472 (80.8) 273 (88.9) 199 (71.8) < .0001*
Consideration of High Risk Test Result: High T2D Risk 487 (83.3) 262 (85.3) 225 (80.9) 0.1541
Intention
Change in Willingness: Testing is Cost-free 442 (74.3) 302 (96.8) 140 (49.5) < .0001*
Change in Willingness: Knowing T2D is Preventable 482 (81.0) 304 (97.4) 178 (62.9) < .0001*
*P-value remains signiﬁcant after Bonferonni correction; p<0.007.
doi:10.1371/journal.pone.0147071.t002
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associated with increased interest in genetic testing were motivation, behavioral intention and
trust. Specifically, motivation associated with high perceived personal risk of T2D [OR = 4.38
(1.76, 10.9)], motivation associated with family history of T2D [OR = 2.56 (1.46, 4.48)], moti-
vation to engage in testing associated with a desire to know risk prior to disease onset
[OR = 3.25 (1.94, 5.42)], motivation associated with knowledge that T2D is a preventable dis-
ease [OR = 2.11 (1.24, 3.60)], and increased intention for genetic testing if free of cost
[OR = 10.2 (4.27, 24.6)] or T2D is preventable [5.18 (1.95, 13.7)]. Distrust of the results of
genetic testing significantly decreased interest in testing [OR = 0.03 (0.003, 0.30)].
Discussion
This study examined demographic and psychosocial factors that predict individual interest in
genetic testing for T2D. Findings from this study build on an emerging literature that has
begun to characterize attitudes about genetic testing for chronic diseases and T2D specifically
in the context of an epidemic of T2D among adults and children. Our findings indicate overall
receptivity and interest in genetic testing for T2D, particularly among those who feel the test is
most relevant to their health status (i.e. high perceived personal risk).
Participants demonstrated relatively high levels of knowledge about genetic testing (genetic
literacy) and awareness that the risk of T2D is increased if there is a family history of the dis-
ease. We observed that preference to know risk prior to diagnosis of T2D and the ability to pre-
vent T2D were significant predictors of interest in testing. In addition, public distrust of the
test emerged as the sole factor predicting rejection of genetic testing for T2D. This suggests that
similar to other forms of health screening, the onus remains on medical and behavioral science
to demonstrate the value of this tool to a generally receptive public. In addition, our data dem-
onstrated that when individuals were told that the cost of testing was free and that T2D can be
prevented, interest in genetic testing increased.
We further observed that only 57% of the sample demonstrated knowledge that T2D is pre-
ventable. More than a decade since the release of the first Diabetes Prevention Program out-
comes paper[24], there remains a significant gap in knowledge between health care
professionals and the public about the ability to prevent this chronic disease. Beyond the public
health implications about diabetes prevention, this gap also has implications for the adoption
of genetic testing. Data from this study suggests that genetic testing for T2D is more highly val-
ued when individuals know there is a way to prevent T2D.
Risk factors such as family history, BMI and metabolic status are currently used by provid-
ers in routine care to advise patients about their risk of developing T2D. Our data suggests
genetic testing for T2D may be most utilized once individuals have been identified as having
Table 3. Psychosocial Predictors of Willingness to Consider Type 2 Diabetes Genetic Testing: Multi-
variable Analysis.
Psychosocial Predictor OR (95% CI)a P-value
Reason for motivation: Individual is high risk (Yes) 4.38 (1.76, 10.9) 0.0015
Reason for motivation: Family history (Yes) 2.56 (1.46, 4.48) 0.0010
Reason for motivation: Prefer to know risk before diagnosis (Yes) 3.25 (1.94, 5.42) < .0001
Reason for motivation: Diabetes is preventable (Yes) 2.11 (1.24, 3.60) 0.0061
Disagree: Do not trust genetic testing results (Yes) 0.03 (0.003, 0.30) 0.0029
Intention: Genetic testing is free of cost (Yes) 10.2 (4.27, 24.6) < .0001
Intention: T2D is preventable (Yes) 5.18 (1.95, 13.7) 0.0010
aAdjusting for Age, BMI, Gender and Recruitment location
doi:10.1371/journal.pone.0147071.t003
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high risk using conventional risk factors. These data also point to the public’s awareness of the
accuracy of medical tests, which will have to be reported clearly when individuals are consider-
ing genetic testing. Likewise the data suggest that the public is more amenable to testing if any
cost incurred by them is eliminated. Finally, these findings demonstrate a disparity between
public knowledge about T2D prevention and interventions that have been empirically demon-
strated to achieve these goals.
These data, along with previous studies, demonstrates public receptivity to genetic testing
among those with and at risk for T2D. One implication for primary care medicine is that provid-
ers can feel confident that their patients are likely to be receptive to genetic testing for risk assess-
ment. At the same time, primary care providers should be aware that their patients may be
utilizing commercial venues that measure their genetic risk only and without their clinical risk has
limited predictive ability. When rigorous and reliable genetic testing information becomes avail-
able, there will be an opportunity for primary care providers to use this information as a teachable
moment and to connect patients to diabetes prevention and education in their community.
Studies investigating characteristics associated with interest in genetic testing to predict risk
of developing T2D or chronic diseases that include T2D are limited. The strengths of our study
are the comprehensive measures of the many psychological constructs related to behavior
change[9–11, 16, 25, 26]; and purposely recruiting individuals representing greater ethnic and
socioeconomic diversity [9, 16, 25, 26].
Limitations of this study included the use of a convenience sample and self-reported risk
factors. Although use of a convenience sample may limit the generalizability of findings, our
large sample size (n = 598) contained substantial variance across demographic characteristics
including age, gender, race, ethnicity, and socio-economic status suggesting that we captured a
broad cross-section of adults. In addition, all data was self-reported, including T2D status. BMI
was estimated from self-reported height and weight and should be interpreted as approxima-
tions to actual values.
Advances in genetic discovery coupled with the decreasing costs of sequencing an individual’s
entire genome have set the stage for personalized medicine to improve health outcomes. There is
a small and growing group of physicians who constitute ‘early adopters’ of this source of informa-
tion who have begun integrating patient’s genetic information into their clinical care. Further
work is needed to make genetic testing for T2D useful for widespread use by primary care provid-
ers. An expanding number of alleles associated with the risk for T2D requires more discovery
research to determine the individual and combined contribution of these SNPs on disease sub-
types, T2D initiation and outcomes. In advance of refined prediction, it is possible that T2D
genetic risk testing may have the most utility in high-risk patient groups. T2D genetic risk testing
may also evolve for use as an intervention early in life to prevent the onset of the risk factors (i.e.
weight, dietary and physical activity behaviors) or to tailor prevention and treatment options to
the individual. Research is needed to develop and test the efficacy and effectiveness of this work
with the goal of reducing the overall burden of T2D in the general population.
Supporting Information
S1 Appendix. Questionnaire.
(DOCX)
Acknowledgments
We are grateful to Dr. Kathryn Coe, Dr. Lisa Staten, Dr. Devon Hensel and Dr. Silvia Bigatti
for providing expert review of the survey instrument designed in this study. We are also
Attitudes towards Genetic Testing for Type 2 Diabetes Risk Prediction
PLOS ONE | DOI:10.1371/journal.pone.0147071 January 20, 2016 10 / 12
grateful to Dr. James Jones, professor of clinical emergency medicine at Indiana University
School of Medicine, for granting us permission to collect data from adults visiting the emer-
gency department at Wishard hospital in Indianapolis. We, additionally, thank the manage-
ment at Indianapolis public libraries for permitting us to collect data from the libraries, and the
Indiana University student volunteers who assisted us in collecting data. The survey instru-
ment was designed using Research Electronic Data Capture (REDCap) professional survey
instrument, hosted by the Indiana Clinical Translational Sciences Institute (CTSI) HUB.
Author Contributions
Conceived and designed the experiments: JW JG MdG. Performed the experiments: JW JG.
Analyzed the data: JW JG. Contributed reagents/materials/analysis tools: JWMdG. Wrote the
paper: JW JG MdG.
References
1. DIAGRAM, Asian Genetic Epidemiology Network Type 2 Diabetes C, South Asian Type 2 Diabetes C,
Mexican American Type 2 Diabetes C, Type 2 Diabetes Genetic Exploration by Nex-generation
sequencing in muylti-Ethnic Samples C, Mahajan A, et al. Genome-wide trans-ancestry meta-analysis
provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014; 46
(3):234–44. doi: 10.1038/ng.2897 PMID: 24509480; PubMed Central PMCID: PMC3969612.
2. Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, et al. Low-frequency and rare
exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun.
2015; 6:5897. doi: 10.1038/ncomms6897 PMID: 25631608.
3. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation
research in genomic medicine: how can we accelerate the appropriate integration of human genome
discoveries into health care and disease prevention? Genetics in medicine: official journal of the Ameri-
can College of Medical Genetics. 2007; 9(10):665–74. PMID: 18073579.
4. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to
common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008; 359(21):2208–19. Epub
2008/11/21. doi: 10.1056/NEJMoa0804742 PMID: 19020323; PubMed Central PMCID: PMC2746946.
5. Vassy JL, Hivert MF, Porneala B, Dauriz M, Florez JC, Dupuis J, et al. Polygenic type 2 diabetes predic-
tion at the limit of common variant detection. Diabetes. 2014; 63(6):2172–82. doi: 10.2337/db13-1663
PMID: 24520119; PubMed Central PMCID: PMC4030114.
6. Belsky DW, Moffitt TE, Houts R, Bennett GG, Biddle AK, Blumenthal JA, et al. Polygenic Risk, Rapid
Childhood Growth, and the Development of Obesity: Evidence From a 4-Decade Longitudinal StudyPo-
lygenic Risk for Adult Obesity. Arch Pediatr Adolesc Med. 2012; 166(6):515–21. Epub 2012/06/06. doi:
10.1001/archpediatrics.2012.131 PMID: 22665028.
7. InterAct C, Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O, et al. The link between fam-
ily history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors:
the EPIC-InterAct study. Diabetologia. 2013; 56(1):60–9. doi: 10.1007/s00125-012-2715-x PMID:
23052052; PubMed Central PMCID: PMCPMC4038917.
8. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, et al. Effects of communicating
DNA-based disease risk estimates on risk-reducing behaviours. The Cochrane database of systematic
reviews. 2010;(10: ):CD007275. doi: 10.1002/14651858.CD007275.pub2 PMID: 20927756.
9. Grant RW, O'Brien KE, Waxler JL, Vassy JL, Delahanty LM, Bissett LG, et al. Personalized genetic risk
counseling to motivate diabetes prevention: a randomized trial. Diabetes Care. 2013; 36(1):13–9. Epub
2012/08/31. doi: 10.2337/dc12-0884 PMID: 22933432; PubMed Central PMCID: PMCPMC3526219.
10. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic
testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009; 52(11):2299–305. Epub
2009/09/04. doi: 10.1007/s00125-009-1512-7 PMID: 19727660.
11. Morren M, Rijken M, Baanders AN, Bensing J. Perceived genetic knowledge, attitudes towards genetic
testing, and the relationship between these among patients with a chronic disease. Patient education
and counseling. 2007; 65(2):197–204. Epub 2006/08/31. S0738-3991(06)00230-8 [pii] doi: 10.1016/j.
pec.2006.07.005 PMID: 16939709.
12. Henderson G, Garrett J, Bussey-Jones J, Moloney ME, Blumenthal C, Corbie-Smith G. Great expecta-
tions: views of genetic research participants regarding current and future genetic studies. Genetics in
medicine: official journal of the American College of Medical Genetics. 2008; 10(3):193–200. Epub
2008/03/18. doi: 10.1097/GIM.0b013e318164e4f5 PMID: 18344709.
Attitudes towards Genetic Testing for Type 2 Diabetes Risk Prediction
PLOS ONE | DOI:10.1371/journal.pone.0147071 January 20, 2016 11 / 12
13. Botoseneanu A, Alexander JA, Banaszak-Holl J. To test or not to test? The role of attitudes, knowledge,
and religious involvement among U.S. adults on intent-to-obtain adult genetic testing. Health education
& behavior: the official publication of the Society for Public Health Education. 2011; 38(6):617–28.
Epub 2011/04/13. doi: 10.1177/1090198110389711 PMID: 21482703.
14. Kaphingst KA, McBride CM, Wade C, Alford SH, Brody LC, Baxevanis AD. Consumers' use of web-
based information and their decisions about multiplex genetic susceptibility testing. J Med Internet Res.
2010; 12(3):e41. Epub 2010/10/05. doi: 10.2196/jmir.1587 v12i3e41 [pii]. PMID: 20884465; PubMed
Central PMCID: PMC2956320.
15. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease
risk. N Engl J Med. 2011; 364(6):524–34. Epub 2011/01/14. doi: 10.1056/NEJMoa1011893 PMID:
21226570.
16. Calsbeek H, Morren M, Bensing J, Rijken M. Knowledge and attitudes towards genetic testing: a two
year follow-up study in patients with asthma, diabetes mellitus and cardiovascular disease. Journal of
genetic counseling. 2007; 16(4):493–504. Epub 2007/02/24. doi: 10.1007/s10897-006-9085-9 PMID:
17318450.
17. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Characteristics of users of
online personalized genomic risk assessments: implications for physician-patient interactions. Genet-
ics In Medicine: Official Journal Of The American College Of Medical Genetics. 2009; 11(8):582–7.
18. Markowitz SM, Park ER, Delahanty LM, O'Brien KE, Grant RW. Perceived impact of diabetes genetic
risk testing among patients at high phenotypic risk for type 2 diabetes. Diabetes care. 2011; 34(3):568–
73. Epub 2011/02/03. doi: 10.2337/dc10-1960 PMID: 21285385; PubMed Central PMCID:
PMC3041182.
19. De Vellis RF. Scale Development. Theory and Applications. 3rd ed. Los Angeles: SAGE; 2012.
20. Glanz K, Rimer BK, Viswanath K. Health Behavior and Health Education: Theory, Research, and Prac-
tice. San Francisco: Jossey-Bass; 2008.
21. Turner-Bowker DM, Bartley PJ, Ware JE Jr.. Health Survey & “SF” Bibliography: Third Edition (1988–
2000). Lincoln, RI: QualityMetric Incorporated; 2002.
22. Furr LA, Kelly SE. The Genetic Knowledge Index: developing a standard measure of genetic knowl-
edge. Genet Test. 1999; 3(2):193–9. PMID: 10464667.
23. Molster C, Charles T, Samanek A, O'Leary P. Australian study on public knowledge of human genetics
and health. Public Health Genomics. 2009; 12(2):84–91. doi: 10.1159/000164684 PMID: 19039252.
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the
incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6):393–
403. Epub 2002/02/08. doi: 10.1056/NEJMoa012512 PMID: 11832527; PubMed Central PMCID:
PMC1370926.
25. Bates MD, Griffin MT, Killion CM, Fitzpatrick JJ. African-American males' knowledge and attitudes
toward genetic testing and willingness to participate in genetic testing: a pilot study. J Natl Black Nurses
Assoc. 2011; 22(1):1–7. Epub 2011/09/06. PMID: 21888145.
26. Liljestrom B, Aktan-Collan K, Isomaa B, Sarelin L, Uutela A, Groop L, et al. Genetic testing for maturity
onset diabetes of the young: uptake, attitudes and comparison with hereditary non-polyposis colorectal
cancer. Diabetologia. 2005; 48(2):242–50. Epub 2005/01/22. doi: 10.1007/s00125-004-1629-7 PMID:
15660263.
Attitudes towards Genetic Testing for Type 2 Diabetes Risk Prediction
PLOS ONE | DOI:10.1371/journal.pone.0147071 January 20, 2016 12 / 12
